Johnson & Johnson (NYSE:JNJ) dropped topline results on Tuesday from Study 452, its second pivotal Phase 3 trial evaluating CAPLYTA (lumateperone) in adults with bipolar I disorder. And the news was good: the therapy met its primary and key secondary endpoints, producing rapid, sustained relief in manic symptoms and overall illness severity compared with a placebo.
Building on favorable data from the earlier Study 451, these new findings provide consistent clinical validation across two late-stage trials. The healthcare company plans to use this combined evidence to support its upcoming U.S. regulatory submission.
Study 452 operated as a global, randomized, double-blind trial that evaluated a once-daily 42 mg dose of CAPLYTA against a placebo over a three-week treatment duration. Investigators enrolled adult patients diagnosed with manic episodes, with or without mixed features, linked to bipolar I disorder.
Rapid Reduction In Manic Symptoms
CAPLYTA achieved its primary efficacy endpoint by generating a statistically significant improvement in the Young Mania Rating Scale (YMRS) total score relative to placebo at Week 3. Patients who received the treatment recorded a 3.7-point greater reduction in scores than those in the placebo group, delivering an effect size of -0.43.
Clinical benefits appeared as early as Day 3 and persisted through the third week. Additionally, nearly twice as many treated participants achieved a clinical response by Week 3. Specifically, 43.9% of patients who received CAPLYTA posted at least a 50% improvement from baseline on their YMRS total scores, compared to 23.7% of participants on placebo.
Illness Severity And Favorable Tolerability
The trial also met its key secondary endpoint by curbing overall illness severity. Patients receiving CAPLYTA exhibited significantly superior outcomes on the Clinical Global Impression–Severity (CGI-S) scale versus placebo at Week 3, with noticeable improvements starting on Day 3.
CAPLYTA demonstrated favorable tolerability alongside low discontinuation rates, maintaining a safety profile consistent with prior clinical data. The most common treatment-related adverse events occurring at an incidence of at least 5% with CAPLYTA, and at double the placebo rate, included dizziness, dry mouth, and somnolence or sedation.
JNJ Price Action: Johnson & Johnson shares were down 1.25% at $277.26 at the time of publication on Wednesday. The stock is approaching its 52-week high of $283.25, according to market data.
